This partnership will allow IRIS to license AEYE Diagnostic Screening (AEYE-DS), an FDA-cleared AI technology for autonomous detection of diabetic retinopathy (DR).
Intelligent Retinal Imaging Systems (IRIS) has partnered with AEYE Health. According to the news release1, the agreement will allow IRIS to license AEYE Diagnostic Screening (AEYE-DS) from AEYE Health. This system is an FDA-cleared AI technology that seamlessly integrates with the IRIS Solution.
This partnership will enable IRIS customers to use AEYE-DS for the autonomous detection of diabetic retinopathy (DR) alongside the IRIS Solution, providing an instantaneous result using only one image per eye. In an FDA clinical study (clearance K221183) for the detection of more-than-mild diabetic retinopathy, the AEYE-DS was found to have 93% sensitivity and over 91.4% specificity using one image per eye captured by the Topcon NW400 fundus camera.1
In the press release1, Steve Martin, CEO of IRIS shared how this partnership will benefit current IRIS users. He said, "We are pleased to partner with AEYE Health. Now a number of IRIS customers can utilize the best-in-class artificial intelligence tool for the early detection of diabetic retinopathy. Their unique single-image-per-eye screening requires less work and produces superior accuracy as demonstrated in their clinical trial. Furthermore, we are excited about the additional camera models that will be available for use with AEYE-DS in the future."
Similarly, Zack Dvey-Aharon, PhD, Co-Founder & CEO of AEYE Health commented in the release1 on the value of this partnership and the footprint of the combined network of providers and clinics. He said, "This partnership with IRIS allows AEYE Health to reach a higher level of adoption due to IRIS's impressive footprint in over 600 clinics, pharmacies, and labs. In the future, our hope is to provide a camera option that IRIS customers can leverage in the 150,000 annual DR screenings that are performed during in-home visits."
Intelligent Retinal Imaging Systems' (IRIS) mission is to end preventable blindness. Their end-to-end comprehensive diagnostic solution enables the provision of retinal imaging services in a variety of settings to persons at risk for developing sight-threatening diseases. The IRIS software is an FDA Class II cleared cloud-based platform which offers clients the unique ability to customize their program from hardware to workflow, ultimately improving quality, increasing access, and reducing costs, but most importantly helping to end vision loss due to diabetic retinopathy. For more information, visit www.retinalscreenings.com.
About AEYE Health
AEYE Health is a digital health company that provides fully autonomous, AI-based diagnostic screening solutions for retinal imaging with best-in-class clinical results and superior usability including single-image-per-eye screening. The company aims to make diagnostic screening practical, accurate and accessible. AEYE Health enables point-of-care screening for diabetic retinopathy to ensure that diabetics are regularly screened for diabetic retinopathy.